FDA Adverse Event Reports on Statin-Associated Rhabdomyolysis

OBJECTIVE: To determine the number of cases of statin-associated rhabdomyolysis reported to the Food and Drug Administration for 6 statins and to profile the cases. METHODS: A retrospective analysis of all domestic and foreign reports of statin-associated rhabdomyolysis between November 1997 and March 2000 was conducted. Outcome measures included the total number of reports (initial plus follow-up), the number of unique cases, age, gender, percentages of report codes and role codes, and frequencies of concomitant interacting drugs that may have precipitated rhabdomyolysis, outcomes codes, and report source codes. RESULTS: There were 871 reports of statin-associated rhabdomyolysis in the 29-month time frame examined, representing 601 cases. The following number of cases were associated with each of the individual statins: simvastatin, 215 (35.8%); cerivastatin, 192 (31.9%); atorvastatin, 73 (12.2%); pravastatin, 71 (11.8%); lovastatin, 40 (6.7%); and fluvastatin, 10 (1.7%). Drugs that may have interacted with the statins were present in the following number of cases: mibefradil (n = 99), fibrates (n = 80), cyclosporine (n = 51), macrolide antibiotics (n = 42), warfarin (n = 33), digoxin (n = 26), and azole antifungals (n = 12). The reports of 62.1% of cases were classified as expedited. Statins were designated as the primary suspect in 72.0% of the cases. Death was listed as the outcome in 38 cases. The majority of reports (n = 556) were from health professionals. CONCLUSIONS: Compared with the other statins, simvastatin and cerivastatin were implicated in a relatively higher number of reports. Because of the various limitations of a spontaneous reporting-system database, caution is urged when interpreting the relative number of cases reported.

[1]  D. Kennedy,et al.  Spontaneous Reporting in the United States , 2002 .

[2]  James P. Wilson,et al.  Rhabdomyolysis and HMG-CoA Reductase Inhibitors , 2001, The Annals of pharmacotherapy.

[3]  Allen Shek,et al.  Statin—Fibrate Combination Therapy , 2001, The Annals of pharmacotherapy.

[4]  P. Honig,et al.  Risk management of marketed drugs: FDA and the interface with the practice of medicine , 2001, Pharmacoepidemiology and drug safety.

[5]  M. Linton,et al.  Current perspectives on statins. , 2000, Circulation.

[6]  R. Herman,et al.  Drug interactions and the statins. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[7]  Sean C. Sweetman,et al.  Martindale: The Complete Drug Reference , 1999 .

[8]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[9]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[10]  A. Gotto,et al.  Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). , 1997, The American journal of cardiology.

[11]  Martin H. Abramson,et al.  Complete Drug Reference , 1996 .

[12]  T. Pedersen,et al.  Benefits and Risks of HMG-CoA Reductase Inhibitors in the Prevention of Coronary Heart Disease , 1996 .

[13]  T. Pedersen,et al.  Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. , 1996, Drug safety.

[14]  W. Garnett Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. , 1995, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[15]  Sarah A. Spinier,et al.  Comparative Evaluation of the Safety and Efficacy of HMG-CoA Reductase Inhibitor Monotherapy in the Treatment of Primary Hypercholesterolemia , 1995, The Annals of pharmacotherapy.

[16]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[17]  B Begaud,et al.  False-positives in spontaneous reporting: should we worry about them? , 1994, British journal of clinical pharmacology.

[18]  C. Blum,et al.  Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. , 1994, The American journal of cardiology.

[19]  L. Dayer-Berenson Rhabdomyolysis: a comprehensive guide. , 1994, ANNA journal.

[20]  D. Illingworth,et al.  A review of clinical trials comparing HMG-CoA reductase inhibitors. , 1994, Clinical therapeutics.

[21]  B. Weisser,et al.  A Comparative Review of the Adverse Effects of Treatments for Hyperlipidaemia , 1991, Drug safety.

[22]  Y. Berland,et al.  Rhabdomyolysis with simvastatin use. , 1991, Nephron.

[23]  T. Gross,et al.  Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. , 1990, JAMA.

[24]  P. Drouin,et al.  Safety, Tolerability, and Efficacy of Simvastatin and Fenofibrate - A Multicenter Study , 1990 .

[25]  P. Drouin,et al.  Safety, tolerability, and efficacy of simvastatin and fenofibrate--a multicenter study. Simvastatin-Fenofibrate Study Group. , 1990, Cardiology.

[26]  A. Stalenhoef,et al.  Efficacy and tolerability of simvastatin (MK-733). , 1989, The American journal of medicine.

[27]  A. Hartzema,et al.  Drug Utilization Study Methodologies: National and International Perspectives , 1987, Drug intelligence & clinical pharmacy.